Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Hoffmann F, Franzen A, de Vos L, Wuest L, Kulcsár Z, Fietz S, Maas AP, Hollick S, Diop MY, Gabrielpillai J, Vogt T, Kuster P, Zarbl R, Dietrich J, Kristiansen G, Brossart P, Landsberg J, Strieth S, Dietrich D. Hoffmann F, et al. Among authors: brossart p. Clin Epigenetics. 2023 Jul 6;15(1):112. doi: 10.1186/s13148-023-01525-6. Clin Epigenetics. 2023. PMID: 37415208 Free PMC article.
Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
Dietrich D, Weider S, de Vos L, Vogt TJ, Färber M, Zarbl R, Hunecke A, Glosch AK, Gabrielpillai J, Bootz F, Bauernfeind FG, Kramer FJ, Kristiansen G, Brossart P, Strieth S, Franzen A. Dietrich D, et al. Among authors: brossart p. Clin Chem. 2023 Sep 1;69(9):1050-1061. doi: 10.1093/clinchem/hvad084. Clin Chem. 2023. PMID: 37477541
Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Möhring C, Mańczak A, Timotheou A, Sadeghlar F, Zhou T, Mahn R, Monin MB, Toma M, Feldmann G, Brossart P, Köksal M, Sarria GR, Sommer N, Lingohr P, Jafari A, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: brossart p. Int J Cancer. 2023 Aug 1;153(3):609-622. doi: 10.1002/ijc.34511. Epub 2023 May 5. Int J Cancer. 2023. PMID: 36919950
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial.
Wiegand S, Wichmann G, Vogt J, Vogel K, Franke A, Kuhnt T, Lordick F, Scheuble AM, Hambsch P, Brossart P, Bauernfeind FG, Kaftan H, Maschmeyer G, Paland M, Münter M, Lewitzki V, Rotter N, Stromberger C, Beck M, Dommerich S, Gauler TC, Hapke G, Guntinas-Lichius O, Schröder U, Görner M, Hautmann MG, Steger F, Tamaskovics B, Schmiedeknecht A, Dietz A. Wiegand S, et al. Among authors: brossart p. Front Oncol. 2023 Mar 21;13:1128176. doi: 10.3389/fonc.2023.1128176. eCollection 2023. Front Oncol. 2023. PMID: 37025596 Free PMC article.
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Möhring C, Frontado Graffe FJ, Bartels A, Sadeghlar F, Zhou T, Mahn R, Marinova M, Feldmann G, Brossart P, Glowka TR, Kalff JC, Strassburg CP, Gonzalez-Carmona MA. Möhring C, et al. Among authors: brossart p. J Gastrointest Oncol. 2023 Feb 28;14(1):352-365. doi: 10.21037/jgo-22-632. Epub 2023 Feb 15. J Gastrointest Oncol. 2023. PMID: 36915455 Free PMC article.
340 results